- Home
- NTRB vs MIRA Comparison
NTRB vs MIRA Comparison
Compare NTRB & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | MIRA |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.0M | 61.1M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NTRB | MIRA |
|---|---|---|
| Price | $4.44 | $1.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 63.5K | ★ 125.5K |
| Earning Date | 12-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,278,321.00 | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $4.17 | $0.73 |
| 52 Week High | $11.78 | $2.45 |
Technical Indicators
Market Signals| Indicator | NTRB | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 44.75 |
| Support Level | $4.25 | $1.38 |
| Resistance Level | $4.74 | $1.48 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 71.94 | 34.37 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.